Previous Close | 2.2400 |
Open | 2.3100 |
Bid | 2.2600 x 800 |
Ask | 2.2800 x 1000 |
Day's Range | 2.2404 - 2.4379 |
52 Week Range | 1.1500 - 9.0800 |
Volume | 47,217 |
Avg. Volume | 89,209 |
Market Cap | 63.294M |
Beta (3Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try...
The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be awareRead More...